Literature DB >> 21775429

Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.

Lihua Jin1, Shengchen Lin, Hui Rong, Songyang Zheng, Shikan Jin, Rui Wang, Yong Li.   

Abstract

Iloprost is a prostacyclin analog that has been used to treat many vascular conditions. Peroxisome proliferator-activated receptors (PPARs) are ligand-regulated transcription factors with various important biological effects such as metabolic and cardiovascular physiology. Here, we report the crystal structures of the PPARα ligand-binding domain and PPARδ ligand-binding domain bound to iloprost, thus providing unambiguous evidence for the direct interaction between iloprost and PPARs and a structural basis for the recognition of PPARα/δ by this prostacyclin analog. In addition to conserved contacts for all PPARα ligands, iloprost also initiates several specific interactions with PPARs using its unique structural groups. Structural and functional studies of receptor-ligand interactions reveal strong functional correlations of the iloprost-PPARα/δ interactions as well as the molecular basis of PPAR subtype selectivity toward iloprost ligand. As such, the structural mechanism may provide a more rational template for designing novel compounds targeting PPARs with more favorable pharmacologic impact based on existing iloprost drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775429      PMCID: PMC3173080          DOI: 10.1074/jbc.M111.266023

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Has angiogenesis been invited to the PPARty?

Authors:  Philip M Barger
Journal:  J Mol Cell Cardiol       Date:  2002-07       Impact factor: 5.000

Review 2.  Activation of nuclear receptors: a perspective from structural genomics.

Authors:  Yong Li; Millard H Lambert; H Eric Xu
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

3.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

4.  Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1.

Authors:  Yong Li; Mihwa Choi; Greg Cavey; Jennifer Daugherty; Kelly Suino; Amanda Kovach; Nathan C Bingham; Steven A Kliewer; H Eric Xu
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

5.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.

Authors:  H E Xu; M H Lambert; V G Montana; K D Plunket; L B Moore; J L Collins; J A Oplinger; S A Kliewer; R T Gampe; D D McKee; J T Moore; T M Willson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.

Authors:  H E Xu; M H Lambert; V G Montana; D J Parks; S G Blanchard; P J Brown; D D Sternbach; J M Lehmann; G B Wisely; T M Willson; S A Kliewer; M V Milburn
Journal:  Mol Cell       Date:  1999-03       Impact factor: 17.970

7.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

Authors:  M M Hoeper; M Schwarze; S Ehlerding; A Adler-Schuermeyer; E Spiekerkoetter; J Niedermeyer; M Hamm; H Fabel
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 8.  PPAR signaling in the control of cardiac energy metabolism.

Authors:  P M Barger; D P Kelly
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

9.  Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors.

Authors:  R Pola; E Gaetani; A Flex; T R Aprahamian; M Bosch-Marcé; D W Losordo; R C Smith; P Pola
Journal:  J Mol Cell Cardiol       Date:  2004-03       Impact factor: 5.000

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more
  12 in total

Review 1.  Vascular effects of prostacyclin: does activation of PPARδ play a role?

Authors:  Zvonimir S Katusic; Anantha V Santhanam; Tongrong He
Journal:  Trends Pharmacol Sci       Date:  2012-06-23       Impact factor: 14.819

Review 2.  Activation of PPARδ: from computer modelling to biological effects.

Authors:  Shirin Kahremany; Ariela Livne; Arie Gruzman; Hanoch Senderowitz; Shlomo Sasson
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling.

Authors:  Trisha Bansal; Emeli Chatterjee; Jasdeep Singh; Arjun Ray; Bishwajit Kundu; V Thankamani; Shantanu Sengupta; Sagartirtha Sarkar
Journal:  J Biol Chem       Date:  2017-08-18       Impact factor: 5.157

Review 4.  The expansive role of oxylipins on platelet biology.

Authors:  Jennifer Yeung; Megan Hawley; Michael Holinstat
Journal:  J Mol Med (Berl)       Date:  2017-05-20       Impact factor: 4.599

Review 5.  ROR nuclear receptors: structures, related diseases, and drug discovery.

Authors:  Yan Zhang; Xiao-yu Luo; Dong-hai Wu; Yong Xu
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

6.  Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes.

Authors:  W Zheng; X Feng; L Qiu; Z Pan; R Wang; S Lin; D Hou; L Jin; Y Li
Journal:  Diabetologia       Date:  2012-11-23       Impact factor: 10.122

7.  Role of prostacyclin signaling in endothelial production of soluble amyloid precursor protein-α in cerebral microvessels.

Authors:  Tongrong He; Anantha Vijay R Santhanam; Tong Lu; Livius V d'Uscio; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-20       Impact factor: 6.200

8.  Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.

Authors:  Yun Chen; Shengju Yang; Wenjuan Yao; Hongyan Zhu; Xiaole Xu; Guoliang Meng; Wei Zhang
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

9.  Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.

Authors:  Vinicius G Maltarollo; Marie Togashi; Alessandro S Nascimento; Kathia M Honorio
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

Review 10.  Targeting nuclear receptors with marine natural products.

Authors:  Chunyan Yang; Qianrong Li; Yong Li
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.